ArticleCancer discovery2022
AACR Project GENIE: 100,000 Cases and Beyond.
Article in Cancer discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 99 citations in OpenAlex.
- Clinical and genomic determinants of early treatment discontinuation in non-small-cell lung cancer: an analysis of the AACR Project GENIE Biopharma Collaborative NSCLC dataset.ESMO real world data and digital oncology · 2026Article
- Comprehensive Analysis of Fraction of Genome Altered in Prostate Cancer Treatment.The Prostate · 2026Article
- Patient-Level KRAS G12C Prevalence among Hispanic/Latino and Non-Hispanic White Patients in Real-world Clinicogenomic Cohorts.Cancer research communications · 2026Article
- Worldwide Innovative Network Consortium: Building a Common Global Cancer Database.JCO global oncology · 2026Review
- Evolving patterns of co-mutations from tumor initiation to metastatic progression.Nature genetics · 2026Article
- Impact of somatic PIK3CA mutations on clinical outcomes in HER2-positive breast cancer.Breast cancer research : BCR · 2026Article
- Omics-based Cancer Prognosis Across Ethnic Groups: From Feature Engineering to Disparity Detection and Mitigation.IEEE transactions on artificial intelligence · 2026Article
- Comparative genomic landscape of primary and metastatic bladder urothelial carcinoma in a large-scale cohort.International journal of clinical oncology · 2026Article
- Comprehensive Genomic Profiling for Precision Oncology: Analytical Validation and Clinical Utility in Solid Tumors.Diagnostics (Basel, Switzerland) · 2026Article
- Convergence of machine learning and genomics for precision oncology.Nature reviews. Cancer · 2026Review
- Implementing generative artificial intelligence in precision oncology: safety, governance, and significance.Journal of hematology & oncology · 2026Review
- Going beyond genomics in precision oncology.Nature medicine · 2026Article
- Real-world clinical utility of comprehensive genomic profiling in advanced solid tumors.Nature medicine · 2026Article
- Harnessing AACR Project GENIE to Define the Molecular Features of Desmoplastic Small Round Cell Tumor.Current issues in molecular biology · 2026Article
- Targeted therapies in lung cancer: personalizing treatment across the age spectrum.Frontiers in oncology · 2026Review
- A paired sequencing study of goblet cell adenocarcinomas with coincident sessile serrated lesions and low-grade appendiceal mucinous neoplasms.Virchows Archiv : an international journal of pathology · 2025Article
- IGF-1R inhibitors in cancer: A review of available evidence and future outlook.Critical reviews in oncology/hematology · 2025Review
- Large language model processing capabilities of ChatGPT 4.0 to generate molecular tumor board recommendations-a critical evaluation on real world data.The oncologist · 2025Article
- AI cancer driver mutation predictions are valid in real-world data.Nature communications · 2025Article
- Large language models enable tumor-type classification and localization of cancers of unknown primary from genomic data.Cell reports. Medicine · 2025Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 11 institutions in 3 countries.
Funding
Abstract
The American Association for Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) is an international pan-cancer registry with the goal to inform cancer research and clinical care worldwide. Founded in late 2015, the milestone GENIE 9.1-public release contains data from >110,000 tumors from >100,000 people treated at 19 cancer centers from the United States, Canada, the United Kingdom, France, the Netherlands, and Spain. Here, we demonstrate the use of these real-world data, harmonized through a centralized data resource, to accurately predict enrollment on genome-guided trials, discover driver alterations in rare tumors, and identify cancer types without actionable mutations that could benefit from comprehensive genomic analysis. The extensible data infrastructure and governance framework support additional deep patient phenotyping through biopharmaceutical collaborations and expansion to include new data types such as cell-free DNA sequencing. AACR Project GENIE continues to serve a global precision medicine knowledge base of increasing impact to inform clinical decision-making and bring together cancer researchers internationally. SIGNIFICANCE: AACR Project GENIE has now accrued data from >110,000 tumors, placing it among the largest repository of publicly available, clinically annotated genomic data in the world. GENIE has emerged as a powerful resource to evaluate genome-guided clinical trial design, uncover drivers of cancer subtypes, and inform real-world use of genomic data. This article is highlighted in the In This Issue feature, p. 2007.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.